ARTICLES BY CLIFF MINTZ
-
Antibacterial Drug Discovery And Beyond7/11/2011
To bolster its therapeutic MAb (monoclonal antibody) development pipeline, in 2006, AstraZeneca purchased United Kingdom-based Cambridge Antibody Technology, and shortly thereafter, in 2007, acquired MedImmune for $15.6B. By Cliff Mintz Ph.D., Life Science Leader magazine
This website uses cookies to ensure you get the best experience on our website. Learn more